Personalized 'Living Drug' tested for tough cancers
NCT ID NCT06767046
Summary
This is an early safety study testing a new type of personalized cell therapy for people with advanced colorectal, pancreatic, or non-small cell lung cancer. The therapy involves collecting a patient's own immune cells, genetically engineering them to target cancer cells with a specific KRAS mutation, and infusing them back. The main goal is to see if this approach is safe and shows early signs of helping control the cancer in patients who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Capital Medical University Affiliated Beijing Ditan Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.